Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaccitech plc
  6. Summary
    VACC   US91864C1071

VACCITECH PLC

(VACC)
  Report
Delayed Nasdaq  -  03:59:53 2023-02-06 pm EST
2.970 USD   -0.67%
01/30Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
GL
01/30Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
AQ
01/30Vaccitech Appoints Nadège Pelletier as Chief Scientific Officer
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/31/2023 02/01/2023 02/02/2023 02/03/2023 02/06/2023 Date
2.83(c) 2.9(c) 2.95(c) 2.99(c) 2.97 Last
39 258 26 995 38 530 36 706 26 578 Volume
-0.70% +2.47% +1.72% +1.36% -0.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 41,2 M - -
Net income 2022 10,5 M - -
Net cash position 2022 214 M - -
P/E ratio 2022 11,5x
Yield 2022 -
Sales 2023 2,10 M - -
Net income 2023 -88,5 M - -
Net cash position 2023 144 M - -
P/E ratio 2023 -1,66x
Yield 2023 -
Capitalization 111 M 111 M -
EV / Sales 2022 -2,50x
EV / Sales 2023 -15,8x
Nbr of Employees 72
Free-Float 36,2%
More Financials
Company
Vaccitech plc, formerly Vaccitech Ltd, is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and... 
Read more
More about the company
Ratings of Vaccitech plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about VACCITECH PLC
01/30Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Offic..
GL
01/30Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Offic..
AQ
01/30Vaccitech Appoints Nadège Pelletier as Chief Scientific Officer
CI
2022Wall Street Gains Support American Depositary Receipts of European Equities
MT
2022Transcript : Vaccitech plc - Special Call
CI
2022Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to ..
AQ
2022VACCITECH PLC Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2022Vaccitech plc Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
2022Earnings Flash (VACC) VACCITECH Posts Q3 Revenue $6.2M
MT
2022Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Development..
GL
2022Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Development..
AQ
2022Vaccitech to Present at Upcoming November Investors Conferences
AQ
2022Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reduct..
AQ
2022Vaccitech plc Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Re..
CI
2022Scancell in-licences SNAPvax technology for its Modi-2 cancer treatment
AN
More news
News in other languages on VACCITECH PLC
01/30Vaccitech nomme Nadège Pelletier au poste de responsable scientifique en chef
2022Les gains de Wall street soutiennent les certificats américains d'actions européennes
2022Vaccitech plc annonce ses résultats pour le troisième trimestre et les neuf mois termin..
2022Vaccitech plc fournit une mise à jour sur l'essai de phase 1b/2a en cours VTP-300 montr..
2022Scancell Holdings plc octroie une licence pour la technologie Vaccitech afin de faire p..
More news
Analyst Recommendations on VACCITECH PLC
More recommendations
Chart VACCITECH PLC
Duration : Period :
Vaccitech plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VACCITECH PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,97 $
Average target price 19,67 $
Spread / Average Target 562%
EPS Revisions
Managers and Directors
William Enright Chief Executive Officer & Director
Gemma Brown Head-Finance Reporting
Robin Wright Chairman
Meg Marshall Chief Medical Officer
Nadège Pelletier Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VACCITECH PLC27.23%112
MODERNA, INC.-3.55%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-1.80%28 711
SEAGEN INC.7.38%25 622